Company / Cash & Equivalents
Vistagen Therapeutics, Inc. Cash & Equivalents History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$16.6M
FY2023
5-year range
$428.5K / $68.1M
FY2019-FY2023
Trend
-75.6%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 8 years, ranging from $81,000 in FY2012 to $68M in FY2022.
Based on SEC 10-K filings.
$17M in FY2023 with a 5-year CAGR of +41.6%.
Improved from $1M to $17M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +41.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +41.6%, indicating consistent growth.
- In FY2023, cash & equivalents decreased 75.6% year-over-year.
- Peak cash & equivalents was recorded in FY2022.
- Lowest cash & equivalents in the period was in FY2012.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $16.6M | -75.6% |
| FY2022 | $68.1M | +4928.1% |
| FY2021 | $1.4M | -53.6% |
| FY2018 | $2.9M | +581.8% |
| FY2017 | $428.5K | -32.8% |
| FY2014 | $638.1K | +687.8% |
| FY2012 | $81.0K | -41.9% |
| FY2011 | $139.3K | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026